Alzheimer’s and Memory Research
About Our Research
The Memory Disorders Program investigates new treatments designed to prevent and slow Alzheimer’s disease. Furthermore, we develop new tools to improve diagnostic and prognostic accuracy.
The Memory Disorders Program is actively recruiting subjects for clinical trials, volunteers are needed to participate in our research. Ongoing studies are those that are underway and are no longer recruiting new subjects.
Recruiting Studies
- Metformin in Alzheimer’s Dementia Prevention (MAP)
- A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer’s Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer’s Disease and Intermediate Amyloid (AHEAD 3-45 Study)
- Longitudinal Early-onset Alzheimer’s Disease Study Protocol (LEADS)
- A Phase 2A Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Varoglutamstat (PQ912) in Patients with Early Alzheimer’s Disease with a Stage Gate to Phase 2B (VIVA-MIND)
- Alzheimer’s Disease Neuroimaging Initiative 4 (ADNI4)
- A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer’s Disease (START STUDY)
- Life’s End Benefits of Cannabidiol and Tetrahydrocannabinol (LiBBY)
Ongoing Studies
- A Study of Donanemab (LY3002813) in Participants With Early Alzheimer’s Disease (TRAILBLAZER-ALZ 2)
- Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4)
- A Study to Confirm Safety and Efficacy of BAN2401 in Participants With Early Alzheimer’s Disease (Clarity AD)
- Longitudinal Evaluation of Amyloid Risk and Neurodegeneration – the LEARN Study (LEARN)
- A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Gantenerumab Administration in Participants With Alzheimer’sDisease (AD) (PostGraduate)
- A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer’s Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 (EMBARK)
- SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer’s Disease (AD) (SIGNAL-AD)
- Memory Improvement Through Nicotine Dosing (MIND) Study (MIND)
- TRC-PAD Program: In-Clinic Trial-Ready Cohort (TRC-PAD)
- A Study of JNJ-63733657 in Participants With Early Alzheimer’s Disease (Autonomy)
- A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer’s Disease (INVOKE-2)
Joining Our Research
As the first step, we invite you to complete a pre-screening phone call. The call lasts 10-15 minutes, and you will be asked about your family and medical history, willingness to participate in research procedures, contact information and demographics. This one time call helps us determine your eligibility for research.
For more information on how to join our research program contact Carolyn Ward, Program Coordinator, at Phone: (202) 784-6671 or Email: cw2@georgetown.edu
Frequently Asked Questions
Please contact us if you have any specific questions.